Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Antioxidant supplementation and serum lipids in patients with Graves' disease: effect on LDL-cholesterol.

Vrca VB, Mayer L, Skreb F, Rahelić D, Marušić S.

Acta Pharm. 2012 Mar;62(1):115-22. doi: 10.2478/v10007-012-0005-2.

PMID:
22472454
2.
3.
4.
5.
6.

The effect of antioxidant vitamin supplementation on traditional cardiovascular risk factors.

Miller ER 3rd, Appel LJ, Levander OA, Levine DM.

J Cardiovasc Risk. 1997 Feb;4(1):19-24.

PMID:
9215516
7.

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ.

N Engl J Med. 2001 Nov 29;345(22):1583-92.

8.

Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.

Kallner G, Vitols S, Ljunggren JG.

J Intern Med. 1996 Jun;239(6):525-9.

PMID:
8656146
9.

Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.

Takata K, Amino N, Kubota S, Sasaki I, Nishihara E, Kudo T, Ito M, Fukata S, Miyauchi A.

Clin Endocrinol (Oxf). 2010 Jun;72(6):845-50. doi: 10.1111/j.1365-2265.2009.03745.x. Epub 2009 Nov 11.

PMID:
19912243
10.

Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease.

Yamada T, Komiya I, Miyahara Y, Komatsu M, Shima I, Inazawa T, Aizawa T.

Endocr J. 2006 Dec;53(6):783-8. Epub 2006 Sep 19.

11.

[Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].

Wu G, Jie Y, Situ Y.

Zhonghua Yi Xue Za Zhi. 2001 Mar 10;81(5):274-5. Chinese.

PMID:
11798886
12.

Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease.

Sewerynek J, Wiktorska J, Nowak D, Lewinski A.

Endocr Regul. 2000 Jun;34(2):83-9.

PMID:
10911409
13.
14.

The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals.

Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, Roussel AM, Favier A, Briançon S.

Arch Intern Med. 2004 Nov 22;164(21):2335-42. Erratum in: Arch Intern Med. 2005 Feb 14;165(3):286.

15.

Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial.

Woodside JV, Yarnell JW, McMaster D, Young IS, Harmon DL, McCrum EE, Patterson CC, Gey KF, Whitehead AS, Evans A.

Am J Clin Nutr. 1998 May;67(5):858-66. Erratum in: Am J Clin Nutr 1998 Sep;68(3):758.

PMID:
9583842
16.

Elevated serum granulocyte colony-stimulating factor levels in patients with Graves' disease.

Iitaka M, Noh JY, Kitahama S, Fukasawa N, Miura S, Kawakami Y, Kawasaki S, Yamanaka K, Ishii J, Katayama S, Ito K.

Clin Endocrinol (Oxf). 1998 Mar;48(3):275-80.

PMID:
9578815
17.
18.

Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.

Corrales JJ, López A, Ciudad J, Mories MT, Miralles JM, Orfao A.

J Endocrinol. 1997 Dec;155(3):491-500.

19.

Enteral feeding with a solution enriched with antioxidant vitamins A, C, and E enhances the resistance to oxidative stress.

Preiser JC, Van Gossum A, Berré J, Vincent JL, Carpentier Y.

Crit Care Med. 2000 Dec;28(12):3828-32.

PMID:
11153621
20.

Antioxidants and methimazole in the treatment of Graves' disease: effect on urinary malondialdehyde levels.

Guerra LN, Ríos de Molina Mdel C, Miler EA, Moiguer S, Karner M, Burdman JA.

Clin Chim Acta. 2005 Feb;352(1-2):115-20.

PMID:
15653105

Supplemental Content

Support Center